Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Oct 17, 2024 · CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in the development of ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Now you know: Updates from my journey living with IPF November 5, 2024; My increasing interest in my family medical history October 29, 2024; Researchers will team up to develop pulmonary fibrosis stem cell models October 25, 2024; Keeping track of meds is part of my post-transplant plan October 22, 2024; Pro-fibrotic immune cell detected in lungs of long COVID-19 patients ...
New prototype therapy may repair IPF lung scarring by …
by Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
Sep 27, 2024 · A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
by Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
PF-associated immune cell detected in lungs of people with long...
Oct 18, 2024 · by Steve Bryson, PhD October 18, 2024. Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent breathing problems after recovering from COVID-19. The cells’ abundance correlated with the severity of fibrosis, or tissue scarring, as detected by CT scans.
Advocating for the idiopathic pulmonary fibrosis community in 2024
Jan 2, 2024 · Samuel Kirton Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in January 2017 began a journey of awareness and advocacy. Sam was listed for a lung transplant on March 19, 2021 and received a bilateral ...
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
Apr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
Phase 3 INOpulse Trial Enrolls First Patient at Risk of...
Dec 4, 2020 · A Phase 3 clinical trial evaluating Bellerophon Therapeutics ’ investigational therapy INOpulse — inhaled nitric oxide — in patients with pulmonary fibrosis (PF) at risk of developing pulmonary hypertension (PH) has enrolled its first patient. Top-line data from the trial, called REBUILD (NCT03267108), are expected by 2022.